NEW YORK (GenomeWeb) – MetaStat today said that it has received Massachusetts licensure for its digital pathology laboratory in Boston.
The company, which provides tissue-based diagnostic tests for predicting cancer metastasis, can begin processing physician orders and run tissue samples from the majority of US states, the final major step to getting certification from the Centers for Medicare and Medicaid Services, it said.
The Boston-based firm provides tests for breast, lung, colorectal, and prostate cancers. Its MetaSite Breast and MenaCalc assays are for stratifying patients based on their tumors' aggressiveness and the risk that their cancers will spread. Both tests are targeted for launch next year as prognostic tools for ER-positive, HER2-negative patients, the company recently told GenomeWeb.